Krystal Biotech, Inc. KRYS Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Krystal Biotech, Inc. (KRYS) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $686K in Q1 2026.
- How has Krystal Biotech, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Krystal Biotech, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 274.9% year-over-year, from $183K to $686K.
- What is the long-term trend for Krystal Biotech, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -54.1% compound annual growth rate (CAGR), from $180K to $8K.